Mersana Therapeutics, Q4 and Earnings Call
Wedbush decreased their Q1 2025 earnings estimates for Mersana Therapeutics in a report issued on Monday, March 3rd. Wedbush ...
Reports Q4 revenue $16.361M, consensus $7.71M. “We made significant progress advancing the clinical development of Emi-Le in 2024,” said Martin ...
Announced positive initial Phase 1 clinical data and an additional Fast Track designation for Emi-Le Initiated first ...
Wedbush reaffirmed their outperform rating on shares of Mersana Therapeutics (NASDAQ:MRSN – Free Report) in a research report ...
Mersana Therapeutics announced promising Phase 1 results for Emi-Le in TNBC and received Fast Track designation from the FDA. Mersana Therapeutics, Inc. announced positive initial Phase 1 clinical ...
On Tuesday, 11 March 2025, Mersana Therapeutics (NASDAQ: MRSN) took center stage at the Leerink Global Healthcare Conference 2025. The company showcased its innovative Antibody-Drug Conjugate (ADC ...
William Blair analyst Andy Hsieh reiterated a Hold rating on Nektar Therapeutics (NKTR – Research Report) today. The company’s shares closed ...
Mersana Therapeutics, Inc. (MRSN) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to loss of $0.16 per share a year ago.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results